Launch of the Phase I Clinical Trial for the FPR2 Agonist Program
First written in FY2018-Q3. 2 of 4 entries say "Cited as achieved", first in FY2018. Latest entry: FY2022-Q3.
No other company in this theme has enough history to compare yet.
- FY2022-Q3DroppedAnnual report
「With respect to the FPR2 agonist program, Bristol-Myers Squibb, the licensee, decided to discontinue development based on its development strategy, and we will receive the return of the development rights and other rights granted to the company.」
Development of the FPR2 agonist program was discontinued for reasons related to the licensee's development strategy, and the development rights and other rights that had been granted will be returned. - FY2019Cited as achievedAnnual report
「Due mainly to a decline from the prior-year level in upfront income recorded in connection with the development progress of the FPR2 agonist program (licensee: Bristol-Myers Squibb, U.S.)」
The development progress of the FPR2 agonist program and the recording of upfront income were cited as prior-year results. - FY2018Cited as achievedAnnual report
「Bristol-Myers Squibb, the licensee, began a Phase I clinical trial of the FPR2 agonist during the third quarter of the fiscal year ending March 2018.」
The start of the Phase I clinical trial for the FPR2 agonist was cited as an annual development milestone for the out-licensed product. - FY2018-Q3First statedAnnual report
「As for the progress of licensed products, Bristol-Myers Squibb, the licensee, began a Phase I clinical trial for the FPR2 agonist program during the third quarter of the consolidated fiscal year.」
The licensee, Bristol-Myers Squibb, began a Phase I clinical trial for the FPR2 agonist program.